Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön Katu 34, 33014, Tampere, Finland.
Department of Obstetrics and Gynecology, Tampere University Hospital, Tampere, Finland.
Qual Life Res. 2024 Apr;33(4):941-949. doi: 10.1007/s11136-023-03575-y. Epub 2024 Jan 18.
Cervical lesions caused by human papillomavirus (HPV) are related to decreased quality of life (QoL) of women. Also, cervical cancer (CC) screening can cause psychological adverse effects. It has been assumed that by decreasing the HPV-related disease burden, HPV vaccinations would increase the QoL. This study compares the effect of CC screening on QoL of HPV vaccinated women in two different screening protocols.
A total of 753 HPV16/18 vaccinated women were randomized to frequent (22/25/28 years of age) and infrequent (28 years of age) CC screening arms. QoL questionnaires (EQ VAS, RAND 36, amended CECA 10) were sent at the age of 28.
Median EQ VAS scores were 80 (Q-Q 75-90) in both screening arms. Mean RAND 36 scores of frequently and infrequently screened women were 78.13/81.64 in Physical role functioning domain and, respectively, 77.93/80.18 in Pain, 69.10/69.12 in General Health, 54.67/53.61 in Energy, 83.72/85.11 in Social functioning, 69.53/69.68 in Emotional role functioning, and 68.16/69.29 in Emotional well-being domain. Among women with a self-reported history of Pap cytology abnormalities, overall mean scores of amended CECA 10 were 69.52/72.07, and among women with a self-reported history of genital warts, 60.09/66.73, respectively.
There was no significant difference in the QoL of HPV vaccinated women between the two CC screening arms. Women were mostly satisfied with the screening experience despite the screening frequency. This information is important for the future screening program planning as we need to reach the best possible balance with screening benefits and harms.
NCT02149030, date of registration 29/5/2014.
人乳头瘤病毒（HPV）引起的宫颈病变与女性生活质量（QoL）下降有关。此外，宫颈癌（CC）筛查可能会引起心理不良反应。人们认为，通过降低 HPV 相关疾病负担，HPV 疫苗接种将提高 QoL。本研究比较了两种不同筛查方案中 CC 筛查对 HPV 疫苗接种女性 QoL 的影响。
共 753 名接种 HPV16/18 的女性被随机分配到频繁（22/25/28 岁）和不频繁（28 岁）CC 筛查组。在 28 岁时发送 QoL 问卷（EQ VAS、RAND 36、修订后的 CECA 10）。
在两个筛查组中，中位 EQ VAS 评分均为 80（Q-Q 75-90）。频繁和不频繁筛查女性的平均 RAND 36 评分分别为生理角色功能领域的 78.13/81.64，疼痛领域的 77.93/80.18，一般健康领域的 69.10/69.12，能量领域的 54.67/53.61，社会功能领域的 83.72/85.11，情绪角色功能领域的 69.53/69.68，情绪健康领域的 68.16/69.29。在自我报告巴氏细胞学异常史的女性中，修订后的 CECA 10 的总体平均得分分别为 69.52/72.07，在自我报告生殖器疣史的女性中，分别为 60.09/66.73。
在两种 CC 筛查方案中，HPV 疫苗接种女性的 QoL 无显著差异。尽管筛查频率较高，但女性对筛查体验大多感到满意。这些信息对于未来的筛查计划规划很重要，因为我们需要在筛查的益处和危害之间达到尽可能好的平衡。
NCT02149030，登记日期 2014 年 5 月 29 日。
